抗血栓治疗与影像引导乳腺空心针活检的血肿风险
这项回顾性多中心研究纳入3311例影像引导乳腺空心针活检,患者继续服用抗血栓药物。结论认为活检前停用抗血栓药物可能不必要;血肿与全剂量抗血小板药、年龄和9G及以上针头相关。
要点
- 临床显著血肿罕见,抗血栓组与非抗血栓组无统计学差异。
- 全剂量抗血小板药、年龄增长和9G及以上针头与血肿率升高相关。
- 超声引导和10-14G针头预示无血肿,支持继续抗血栓治疗。
核心结论
- 临床显著血肿不常见,活检前停用抗血栓药物可能不必要。
- 活检后血肿与全剂量抗血小板药、患者年龄和9G及以上针头相关。
- 未发现其他类型抗血栓药物与血肿的关联。
研究设计与样本
- HIPAA合规的回顾性研究,纳入2019年4月至2021年4月六家学术和六家私人 practice 的3311例活检(2664例患者,中位年龄60岁,IQR 48-70岁,2658例女性)。
- 患者被指示继续服用抗血栓药物,分为抗血栓组(523例)和非抗血栓组(2788例)。
- 活检类型包括超声、立体定向或MRI引导的空心针活检。
- 血肿定义为术后乳腺X线摄影上活检部位新发直径≥2 cm的肿块。
- 临床显著血肿定义为需要手动压迫以外的干预处理。
临床应用与阅片要点
- 活检前可考虑不常规停用抗血栓药物,因临床显著血肿罕见。
- 对服用全剂量抗血小板药、高龄或使用9G及以上针头的患者,应更关注血肿风险。
- 超声引导和较细针头(10-14G)可能降低血肿风险。
局限性
- 回顾性研究设计。
- 未报告样本量计算或功效分析。
- 抗血栓组中部分药物亚型样本量较小(如肝素或依诺肝素仅3例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background For image-guided core-needle breast biopsy (CNBB), it remains unclear whether antithrombotic medication should be withheld because of hematoma risk. Purpose To determine hematoma risk after CNBB in patients receiving antithrombotic medication and to stratify risk by antithrombotic type. Materials and Methods This HIPAA-compliant retrospective study included US-, stereotactic-, or MRI-guided CNBBs performed across six academic and six private practices between April 2019 and April 2021. Patients were instructed to continue antithrombotic medications, forming two groups: antithrombotic and nonantithrombotic. Hematomas were defined as new biopsy-site masses with a diameter of 2 cm or larger on postprocedure mammograms. Hematomas were considered clinically significant if management involved an intervention other than manual compression. Patient age, type of antithrombotic medication, practice type, image guidance modality, needle gauge and type, and outcome of pathologic analysis were recorded. Multivariable logistic regression analysis was used to analyze variables associated with hematomas. Results A total of 3311 biopsies were performed in 2664 patients (median age, 60 years; IQR, 48-70 years; 2658 women). The nonantithrombotic group included 2788 biopsies, and the antithrombotic group included 523 biopsies (328 low-dose aspirin, 73 full-dose antiplatelet drugs, 51 direct oral anticoagulants, 36 warfarin, 32 daily nonsteroidal anti-inflammatory drugs, three heparin or enoxaparin). The antithrombotic group had a higher overall hematoma rate (antithrombotic group: 49 of 523 biopsies [9.4%], nonantithrombotic group: 172 of 2788 biopsies [6.2%]; P = .007), but clinically significant hematoma rates were not different (antithrombotic group: two of 523 biopsies [0.4%], nonantithrombotic group: one of 2788 biopsies [0.04%]; P = .07). At multivariable analysis, age (odds ratio [OR], 1.02; 95% CI: 1.01, 1.03; P < .001), 9-gauge or larger needles (OR, 2.1; 95% CI: 1.28, 3.3; P = .003), and full-dose antiplatelet drugs (OR, 2.5; 95% CI: 1.29, 5.0; P = .007) were associated with higher hematoma rates. US guidance (OR, 0.26; 95% CI: 0.17, 0.40; P < .001) and 10-14-gauge needles (OR, 0.53; 95% CI: 0.36, 0.79; P = .002) were predictive of no hematoma. Conclusion Because clinically significant hematomas were uncommon, withholding antithrombotic medications before core-needle breast biopsy may be unnecessary. Postbiopsy hematomas were associated with full-dose antiplatelet drugs, patient age, and 9-gauge or larger needles. No association was found with other types of antithrombotic medication. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Chang and Yoen in this issue.
引用
- Loving, Johnston, Reddy, et al. Antithrombotic Therapy and Hematoma Risk during Image-guided Core-Needle Breast Biopsy. Radiology. 2022. PMID: 35997610. doi:10.1148/radiol.220548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。